{
  "id": 8303677,
  "title": "Predicting Neoantigen Immunogenicity from In Vivo Immune Editing",
  "url": "https://urgent.news/2026/09/18/predicting-neoantigen-immunogenicity-from-in-vivo-immune-editing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752425v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Neoantigen immunogenicity prediction is fundamental to personalized cancer vaccines, tumor-infiltrating lymphocyte (TIL) therapy, and TCR-T cell engineering. Existing computational predictors rely primarily on in-vitro correlates of peptide presentation or models trained against assay-based reactivity, and they are typically validated within a single therapeutic setting. We reasoned that the most…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}